Vimarsana
Biggest News Aggregation in the World

Page 3 - Timothy Gilbert News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Timothy Gilbert. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Timothy Gilbert Today - Breaking & Trending Today

Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine - Vimarsana News

Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic...

Sanofi: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM - Vimarsana News

Sanofi: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly

Media Update: New data presented at ATS demonstrate Sanofi's leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases - Vimarsana News

Media Update: New data presented at ATS demonstrate Sanofi's leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases

Media Update New data presented at ATS demonstrate Sanofi's leadership in advancing potential new therapies for patients with immune-mediated respiratory...

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia - Vimarsana News

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia underscore the potential of...

Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation -February 23, 2024 at 01:01 am EST - Vimarsana News

Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation -February 23, 2024 at 01:01 am EST

Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation Priority Review granted based on positive results from two Phase 3 trialsIf approved,...